Tislelizumab-jsgr is biosimilar
- TRADE NAME: Tevimbra (BeiGene)
- INDICATIONS:
Indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Immune checkpoint inhibitor (incl. programmed death receptor-1 (PD-1) inhibitor), Monoclonal antibody, Programmed death receptor-1 (PD-1) inhibitor
- HALF-LIFE: 24 days
- FDA APPROVAL DATE: 03/13/2024
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Can cause fetal harm when administered to a pregnant woman. Advise women of the potential risk to a fetus.
Please login to view the rest of this drug profile.
Page last updated 12/07/2025
